←Back to Expert Scholars
Translational Medicine / 转化医学BTK and BCL-2 Combinations
Matthew Davids
MD, MMSc
🏢Dana-Farber Cancer Institute / Harvard Medical School🌐USA
Associate Professor of Medicine
75
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Matthew Davids has led studies combining BTK inhibitors with venetoclax and anti-CD20 antibodies to achieve deep responses and minimal residual disease in CLL. His work supports fixed duration targeted combinations as a new paradigm. He is a core contributor to Dana-Farber CLL clinical trials.
Share:
🧪Research Fields 研究领域
CLL
BTK inhibitors
venetoclax combinations
MRD
fixed duration therapy
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Matthew Davids 的研究动态
Follow Matthew Davids's research updates
留下邮箱，当我们发布与 Matthew Davids（Dana-Farber Cancer Institute / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment